nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.12.2006 | Original article

Comparative benefits and limitations of ¹⁸F-FDG PET and CT-MRI in documented or suspected recurrent cervical cancer

verfasst von: Tzu-Chen Yen, Chyong-Huey Lai, Shih-Ya Ma, Kuan-Gen Huang, Huei-Jean Huang, Ji-Hong Hong, Swei Hsueh, Wuu-Jyh Lin, Koon-Kwan Ng, Ting-Chang Chang

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 12/2006

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study was to assess the comparative benefits and limitations of ¹⁸F-fluorodeoxyglucose (FDG) PET and CT-MRI in documented or suspected recurrence of cervical cancer after primary treatment.

Methods

Three patient groups were enrolled. Group A patients had biopsy-documented recurrent or persistent cervical cancer. Group B patients had suspicion of recurrent tumour on CT-MRI without biopsy proof and were potentially curable. Group C patients were in complete remission after previous definitive treatment for histologically confirmed cervical carcinoma but had elevated serum squamous cell carcinoma antigen (tumour marker) levels despite negative CT-MRI. Clinical management decisions were recorded with CT-MRI alone and with additional FDG PET. Discordances and concordances between CT-MRI and FDG PET results were identified and related to final diagnosis as based on histopathology or follow-up.

Results

A total of 150 patients (ten regions per patient) were eligible for analysis, with 58 in group A, 52 in group B and 40 in group C. For the 149 discordant regions, 126 (84.6%) had final diagnoses. Of these final diagnoses, there was additional benefit from FDG PET over CT-MRI in 73.8% (93/126), with FDG PET correcting false negatives (FNs) on CT-MRI in 74.2% (69/93) and correcting false positives (FPs) on CT-MRI in 25.8% (24/93). Among lesions confirmed by FDG PET, 75.4% (52/69) were extra-pelvic. There was additional benefit of CT-MRI compared with FDG PET in 26.2% (33/126): in nine (27.3%) CT-MRI results were shown to be true positive (TP) whereas FDG PET yielded FN results, while in 24 (72.7%) CT-MRI corrected FP results on FDG PET. Among the nine FNs on FDG PET that were identified by CT-MRI, four were extra-pelvic. Among the FPs on FDG PET that were excluded by CT-MRI, 79.2% (19/24) were extra-pelvic.

Conclusion

For recurrent cervical cancer, the benefits of FDG PET exceed those of CT-MRI owing to the ability of FDG PET to identify extra-pelvic metastases and its higher sensitivity and specificity.

Waggoner SE. Cervical cancer. Lancet 2003;361:2217–2225PubMedCrossRef

Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomized study of radical surgery versus radiotherapy for stage IB-IIA cervical cancer. Lancet 1997;350:535–540PubMedCrossRef

Lai CH, Hong JH, Hsueh S, Ng KK, Chang TC, Tseng CJ, et al. Preoperative prognostic variables and the impact of postoperative adjuvant therapy on the outcomes of stage IB or II cervical carcinoma patients with or without pelvic lymph node metastases. Cancer 1999;85:1537–1546PubMedCrossRef

Burke TW, Hoskins WJ, Heller PB, Shen MC, Weiser EB, Park RC. Clinical patterns of tumor recurrence after radical hysterectomy in stage IB cervical carcinoma. Obstet Gynecol 1987;69:382–385PubMed

Lai CH. Management of recurrent cervical cancer. Chang Gung Med J 2004;72:711–719

Soisson AP, Geszler G, Soper JT, Berchuck A, Clarke-Pearson DL. A comparison of symptomatology, physical examination, and vaginal cytology in the detection of recurrent cervical carcinoma after radical hysterectomy. Obstet Gynecol 1990;76:106–109PubMed

Eralp Y, Saip P, Sakar B, Kucucuk S, Aydiner A, Dincer M, et al. Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix. Int J Gynecol Cancer 2003;13:497–504PubMedCrossRef

Sommers GM, Grigsby PW, Perez CA, Camel HM, Kao MS, Galakatos AE, et al. Outcome of recurrent cervical carcinoma following definitive irradiation. Gynecol Oncol 1989;35:150–155PubMedCrossRef

Hong JH, Tsai CS, Lai CH, Chang TC, Wang CC, Chou HH, et al. Recurrent squamous cell carcinoma of cervix following definitive radiotherapy. Int J Radiat Oncol Biol Phys 2004;60:249–257PubMedCrossRef

10.

Ohara K, Tanaka Y, Tsunoda H, Nishida M, Sugahara S, Itai Y. Assessment of cervical cancer radioresponse by serum squamous cell carcinoma antigen and magnetic resonance imaging. Obstet Gynecol 2002;100:781–787PubMedCrossRef

11.

Chang TC, Law KS, Hong JH, Lai CH, Ng KK, Hsueh S, et al. Positron emission tomography for unexplained serum SCC-Ag elevation in cervical cancer patients—a phase II study. Cancer 2004;101:164–171PubMedCrossRef

12.

Havrilesky LJ, Wong TZ, Secord AA, Berchuck A, Clarke-Pearson DL, Jones EL. The role of PET scanning in the detection of recurrent cervical cancer. Gynecol Oncol 2003;90:186–190PubMedCrossRef

13.

Lai CH, Huang KG, See LC, Yen TC, Tsai CS, Chang TC, et al. Restaging of recurrent cervical cancer with dual-phase¹⁸F-fluoro-2-D-glucose positron-emission tomography. Cancer 2004;100:544–552PubMedCrossRef

14.

Yen TC, See LC, Chang TC, Huang KG, Ng KK, Tang SG, et al. Defining priority of utilizing 18-fluoro-2-deoxyglucose positron emission tomography for recurrent cervical cancer. J Nucl Med 2004;45:1632–1639PubMed

15.

Yen TC, Ng KK, Ma SY, Chou HH, Tsai CS, Hsueh S, et al. Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer. J Clin Oncol 2004;21:3651–3658CrossRef

16.

Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: globocan. Int J Cancer 2001;94:153–156PubMedCrossRef

17.

Drain PK, Holmes KK, Hughes JP, Koutsky LA. Determinants of cervical cancer rates in developing countries. Int J Cancer 2002;100:199–205PubMedCrossRef

18.

Barrington SF, Maisey MN. Skeletal muscle uptake of fluorine-18-FDG: effect of oral diazepam. J Nucl Med 1996;37:1127–1129PubMed

19.

Tatsumi M, Engles MN, Ishimori T, Nicely O, Cohade C, Wahl RL. Intense¹⁸F-FDG uptake in brown fat can be reduced pharmacologically. J Nucl Med 2004;45:1189–1193PubMed

20.

Rockall AG, Sohaib SA, Harisinghani MG, Babar SA, Singh N, Jeyarajah AR, et al. Diagnostic performance of nano-particle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol 2005;23:2813–2821PubMedCrossRef

Titel: Comparative benefits and limitations of 18F-FDG PET and CT-MRI in documented or suspected recurrent cervical cancer
verfasst von: Tzu-Chen Yen
Chyong-Huey Lai
Shih-Ya Ma
Kuan-Gen Huang
Huei-Jean Huang
Ji-Hong Hong
Swei Hsueh
Wuu-Jyh Lin
Koon-Kwan Ng
Ting-Chang Chang
Publikationsdatum: 01.12.2006
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 12/2006
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-006-0090-x

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2006

FDG—a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer

Accuracy of non-invasive techniques for diagnosis of coronary artery disease and prediction of cardiac events in patients with left bundle branch block: a meta-analysis

Fifth European Paediatric Nuclear Medicine Symposium

[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients

Data acquisition and analysis: the strength of methodology in nuclear medicine and molecular imaging

Incidental finding of an 11C-choline PET-positive solitary plasmacytoma lesion